Panayiotis P. Constantinides received a University Diploma in Chemistry from Athens University in 1977 and PhD in Biochemistry from Brown University in 1983. He was a postdoctoral fellow in the Pharmacology Department and Associate Research Scientist in the Comprehensive Cancer Center of Yale University School of Medicine (1983 -1987). Dr. Constantinides since 2004 is the Founder and Principal of Biopharmaceutical & Drug Delivery Consulting, LLC based in Gurnee, IL and currently Affiliated Associate Professor of Pharmaceutical Sciences at Roosevelt University, College of Pharmacy, in Schaumburg, IL. Past industrial positions held included: Vice President of R&D with DOR BioPharma and Morton Grove Pharmaceuticals (2001-2004), Director of Research at SONUS Pharmaceuticals (1997-2000) and from 1987 to 1997 a number of R&D positions of increasing responsibilities with LipoGen, SmithKline Beecham Pharmaceuticals and Abbott Laboratories. He is inventor in 33 patents and patent applications, has authored more than 100 publications/book chapters/abstracts and he has been invited speaker at many national and international conferences, biotech and pharmaceutical companies and universities. Dr. Constantinides is AAPS Fellow, Vice Chair of the AAPS Formulation Design and Development Section, Past Chair of the Nanotechnology and Lipid-Based Drug Delivery Systems Focus Groups.

Biomedical applications of nano materials and nano particles

Sudhakar Akulapalli is a Director of Cell Signaling and Tumor Angiogenesis Laboratory Boys Town National Research Hospital, Omaha NE USA, He is a Clinical Professor Creighton University and Nebraska Medical Center. He did his postdoctoral training at Harvard Medical School Boston USA 2003. He has received PhD 2001 MPhill 1997 and MSc 1995. Degrees in life sciences from University of Hyderabad; and BSc in Biology from SK University 1993 from India He was received President’s fellowship GATE and CSIR fellowships from government of India. He received Mahindra Mahindra Travel Award and YCS Award from FAMRI He received BioBio Young Scientist Award from OMICS and RO1 grant award from NIH/NCI. He is serving as AIBS/NIHGrant reviewer. He has published more than 30 research articles including Science JCI Cancer Cell PNAS Blood etc. He is serving as an Executive Editor and editorial board member of reputed journals and serving as reviewer of 20 scientific journals.

Extracellular matrix and Integrin Signaling
Biology and significance of type IV collagen derived angioinhibitors
Endogenous angioinhibitors role in Cancer and tumor microenvironment
Hypoxic tumorangiogenesis
Mechanism of endothelial apoptosis
Bioequivalence & Bioavailability of endogenous circulating angioinhibitors
He is serving as an editorial board member of reputed

Professor David Brayden is Associate Professor of Advanced Drug Delivery at University College Dublin (UCD), Ireland. He is also the Director of Science Foundation Ireland’s ‘Irish Drug Delivery Network’ research cluster (2007-2013). David is the author / co-author of over 150 publications covering his time as a senior scientist at Elan Corp (1991-2001) as well as at UCD. His lab specializes in oral peptide delivery technologies and bioassays and he consults for the biotech companies. He was made a Fellow of the Controlled Release Society in 2012.

Drug Delivery Systems

Wei-Chiang Shen received his Ph.D. from Boston University and postdoctoral training at Harvard Medical School and Brandeis University. After spending 10 years as a faculty member at Boston University School of Medicine, he joined University of Southern California School of Pharmacy in 1987 and is currently John A. Biles Professor in Pharmaceutical Sciences. He has published more than 130 papers, 13 issued US patents, and the textbook Immunology for Pharmacy Students. Shen is a Fellow of AAPS and AAAS, and was the recipient of the 2002 Eurand Award (Grand Prize) for Outstanding Novel Research in Oral Drug Delivery.

Cancer Treatment, Membranes & Transport, Protein Chemistry/Enzymology, Drug Design, Delivery

He is a Professor of Medicine, Department of Medicine, and Affiliate Faculty, Department of Physiology and Biophysics at the University of Illinois at Chicago, where he has worked since 1993. Dr. Rubinstein is a leading physician and research scientist in respiratory medicine and oncology. He has served on the editorial boards of several medical and scientific journals and is grant reviewer for the NIH. Dr. Rubinstein received an M.D. degree from Hebrew University Hadassah School of Medicine and completed fellowships in Respirology at the University of Toronto and at the Cardiovascular Research Institute of the University of California at San Francisco.

Basic research, Nanomedicine, Targeted drug delivery, Bioimaging

Rakesh K. Srivastava is a Professor in Cancer Research and KBA Eminent Scholar in University of Guelph,Canada.

Cancer biology, angiogenesis, metastasis, transgenic animals, stem cells, biomarkers, transcription factors, drug discovery and development The main focus of my laboratory is to examine the molecular mechanisms of apoptosis, angiogenesis and metastasis, and develop novel drugs for the treatment and prevention of various cancers. We have used biochemical, molecular and transgenic animal approaches to identify novel death receptor agonists. These small molecules bind to death receptors and induce apoptosis in cancer cells, while sparing normal cells. Inhibition of survival pathways have been shown to enhance the therapeutic potential of death receptor agonists. We are examining the molecular mechanisms and preclinical potential of natural products and dietary agents such as resveratrol, curcumin, EGCG, sulforaphane, and diallyl trisulphide for the prevention of various cancers. These compounds appear to enhance the therapeutic potential of death receptor agonists. Furthermore, these agents sensitize those cancer cells that are resistant to chemotherapy and radiotherapy alone. Thus, the use of chemopreventive agents may enhance the therapeutic potential of anticancer drugs, irradiation and death receptor agonists. Chromatin modification has emerged as a new fundamental mechanism for gene transcriptional activity and has been associated with many cellular processes like proliferation, growth, apoptosis, and differentiation. It is increasingly recognized that epigenetic modifications constitute important regulatory mechanisms for the pathogenesis of malignant transformations. The role of epigenetics in diagnosis and treatment is likely to increase as mechanisms leading to the transcriptional silencing of genes involved in human cancers are revealed. Drugs that inhibit methylation are used both as a research tool to assess reactivation of genes silenced in cancer by hypermethylation and in the treatment of malignancies. In addition, the molecular mechanisms by which histone deacetylase inhibitors induce changes in gene expression are being examined. Furthermore, the clinical potentials of HDAC inhibitors and death receptor agonists are being evaluated in several models of human cancer. Recent breakthroughs in stem cell biology, especially the development of induced pluripotent stem cell technique, have generated tremendous enthusiasm and efforts to explore the therapeutic potential of stem cells in human diseases. Progress in stem cell research and the identification of potential stem cells provides hope for the use of stem cells in regenerative medicine, treatment and prevention. The goal is to use adult or tissue-restricted stem cells as a possible approach for the treatment of cancer. We are using small molecules to target specific signaling pathways and/or mechanisms in manipulating cell fate and function. These small molecules are starting to play increasingly important roles in both elucidating the fundamental biology of stem cells and facilitating the development of therapeutic approaches. Such approaches could involve cell replacement therapies using homogenous functional cells produced under chemically defined conditions in vitro and the development of small-molecule based drugs for the treatment of human diseases.

Kanwar is an immunologist and molecular biochemist with an international reputation in investigating fundamental and applied molecular aspects of cancer and chronic inflammation. He did his PhD from Post Graduate Institute of Medical Education and Research PGIMER Chandigarh, India. Before joining Deakin University in 2006, he was a Senior Scientist/Senior Research Fellow in the University of Auckland, Auckland, New Zealand. During the past decade his research both academic and commercial has centered on understanding the pathophysiological mechanisms and/or finding treatments for a variety of chronic inflammatory diseases and different types of cancer.

Profeesor Pierra A. Guertin is at Laval University in Canada in the Psychiatry and Neuroscience Department. He is also the CEO and President of Nordic Life Science Pipeline. He ahas completed his Bsc.( 1986-1989) from University of Montreal and Msc. in Neurokinetic(1990-1992) from University of Quebec at Montreal and Phd. in In Vivo Neurophysiology(1993-1996) from University of Manitoba . He has also been CSO and the co-founder of Eurymedon Healthcare from October 2009- June 2010.

Gabriela Beatriz Acosta has received her PhD in Buenos Aires University (Pharmacology area). Currently, she is working in Institute of Pharmacological Research (ININFA), National Scientific and Technologic Research Council (CONICET) and University of Buenos Aires (UBA). She has successfully completed Administrative responsibilities as Researcher. She is serving as an editorial member of several reputed journals like Brain Research, Neuroscience Letters, Brain Research Bulletin, Neurochemistry International, Int. J. Developmental Neuroscience, Current Chemical Biology, and so on. She has authored 33 international research articles, 10 national research articles and 3 chapters of books. She is a member of National Scientific and Technologic Research Council (CONICET) and University of Buenos Aires (UBA). She has honored as Peer Reviewer of NRR by Editorial Board.

Cao Tong is Vice Dean for Research working in the department of dentistry at National University of Singapore

Differentiated hESC models for toxicological and pharmacological screening/testing, Somatic differentiation of hESC, Tissue regeneration and Stem cells for cell therapy

Horacio Perez-Sanchez ([email protected]) graduated in Theoretical and Computational Chemistry from the University of Murcia (Spain) in 1999, where he also obtained his PhD degree in 2006, which consisted in the development and implementation of computational methodologies for the study of macromolecular systems. He performed research in several European Institutions such as the Institute of Structural Biology (CEA, Grenoble, France), where he successfully developed and applied computational methodologies for the interpretation of macromolecules in solution, and at the Karlsruhe Institute of Technology (Karlsruhe, Germany), where he developed new methodologies for drug discovery and implemented them in parallel architectures such as the Cell Broadband Engine, Graphics Processing Units and Supercomputers.